Bei Akademie registrieren
Fresenius, DE000FRE5EN2

Fresenius stock rises as Q3 strength lifts 2026 outlook

Published on 11/05/2026 at 17:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Fresenius stock advanced after the healthcare group delivered stronger third-quarter results. Management lifted its full-year profitability outlook.

Fresenius strengthens its outlook

  • Third-quarter revenue reached 5.803 billion euros, with organic growth of 5 percent.
  • Core EPS rose 14 percent at constant currency, while the group EBIT margin expanded to 11.0 percent.
  • Fresenius raised its full-year EBIT margin indication and cited stronger performance at Kabi and Helios.
Fresenius, DE000FRE5EN2, Illustration mit AI erstellt.
Fresenius, DE000FRE5EN2, Illustration mit AI erstellt.

Fresenius reported stronger third-quarter operating performance on Wednesday, November 4, and raised its 2026 outlook. In its Q3 results release, the company said organic revenue growth and higher earnings at Fresenius Kabi and Fresenius Helios supported the quarter.

Fresenius stock traded at 52.07 euros on Lang & Schwarz at 17:07 CET on Thursday, November 5, 2026, 1.34 percent above the Xetra close of Wednesday, November 4. The latest quote is also 1.94 percent above the 51.08-euro level cited in the company's relevant Thursday morning report at 08:07 CET, providing the qualifying change for this second main values edition.

Quarterly performance supports guidance

Group revenue reached 5.803 billion euros in the third quarter, up 5 percent organically. Group EBIT before special items rose 10 percent at constant currency to 638 million euros, lifting the EBIT margin by 50 basis points to 11.0 percent.

Core EPS increased 14 percent at constant currency to 0.72 euros. Fresenius linked the improvement to operating performance and lower interest expense following further debt reduction. Core net income rose 14 percent at constant currency to 403 million euros.

Kabi and Helios drive execution

Fresenius Kabi generated 2.304 billion euros of revenue and 391 million euros of EBIT. Its Growth Vectors recorded 9 percent organic revenue growth, led by Biopharma growth of 29 percent. Helios delivered 3.405 billion euros of revenue and 293 million euros of EBIT, with organic revenue growth of 5 percent.

For fiscal 2026, Fresenius now expects constant-currency Core EPS growth in the upper half of its 10 percent to 15 percent range. The group EBIT margin indication was raised to above 11.5 percent from around 11.5 percent previously. The company also reported a net debt to EBITDA ratio of 2.5 times at September 30.

Investors can follow the real-time quote of Fresenius stock.

The DAX provides the relevant German market backdrop for Fresenius stock: current DAX coverage.

More news and analyses on Fresenius stock are available in the topic overview.

Fresenius SE & Co. KGaA

  • ISIN: DE000FRE5EN2
  • Quote: 52.07 euros on Lang & Schwarz, Thursday, November 5, 2026, 17:07 CET
  • Day comparison: 1.34 percent above the Xetra close of Wednesday, November 4, at 51.38 euros
  • Xetra symbol: FRE.DE
Disclaimer...
en | DE000FRE5EN2 | FRESENIUS | boerse | 70465289 |